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ABSTRACT
Background: Death domain-associated protein 6 (DAXX) is involved in regulating apoptosis via subcellular localization. The presence
of DAXX point mutations correlates well with loss of nuclear expression on immunohistochemistry (IHC). In this study, we sought to determine
(1) whether DAXX expression pattern is the same across different uterine carcinoma subtypes, and (2) which uterine carcinomas show loss
of nuclear DAXX IHC.
Design: We studied 65 uterine carcinomas of the following histologic types: 30 endometrioid (12 FIGO [The International Federation of
Gynecology and Obstetrics] grade 1, 12 FIGO grade 2, and 6 FIGO grade 3), 8 serous, 14 clear cell, and 13 undifferentiated/dedifferentiated
type (UEC/DDEC). Nuclear DAXX IHC was assessed in each tumor and was graded semi-quantitatively as follows: 0% to 50%, 50% to 75%,
and greater than 75% of lesional cells react.
Results: A total of 61% (25/41) of high-grade carcinomas (FIGO grade 3, serous, clear cell, and UEC/DDEC]) showed retained DAXX
nuclear staining in >75% of lesional cells, compared with only 4.2% (1/24) of the low-grade carcinomas (FIGO grades 1 and 2) (P = .0001),
where DAXX expression was cytoplasmic. In addition, in the 11 DDEC cases, all the differentiated components showed loss of nuclear DAXX
compared with the undifferentiated components which retained nuclear DAXX expression.
Conclusions: We demonstrate that loss of nuclear DAXX is present in low-grade endometrial carcinomas and the differentiated components in UEC/DDEC, but not in high-grade ones, suggesting DAXX’s role in tumor progression and its potential as a therapeutic target in
high-grade endometrial carcinomas.
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Introduction

Uterine endometrial carcinomas (UECs) are the most common gynecologic neoplasms in the United States.1 They represent a histologically diverse group of tumors with different
pathological features. High-grade endometrial cancers include
serous, clear cell, and undifferentiated/dedifferentiated carcinomas (UEC/DDEC), the latter being more likely to recur/
metastasize while carrying the worst prognosis.2 Currently,
despite increased understanding regarding the molecular pathways involved in the pathogenesis of UEC, the prognosis for
advanced disease is still poor, with options for targeted therapies still lacking.3 An expansion of prognostic and therapeutic
markers in UECs is urgently needed: to reflect the complexity
of the carcinomas, to provide a more accurate stratification, and
to allow for more effective therapies.
Death domain-associated protein-6 (DAXX), a predominantly nuclear protein, was originally death receptor binding
protein. It has been shown to be important for enhancing Fasmediated apoptosis through its interaction with JNK (c-Jun
N-terminal kinase).4,5 The physiological function of DAXX
relies on its ability to shuttle between the nucleus and the cytoplasm.6 It has been reported that in neurons, the function of
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DAXX varies according to its localization: for example, when
DAXX is located in the nucleus, it is anti-apoptotic, whereas
when it is localized in the cytoplasm, it is pro-apoptotic.7 Per
contra, an example of the former is that of diffuse large B-cell
lymphoma, where DAXX is considered a cancer-promoting
(while retained in the nucleus). Therefore, patients who have
high nuclear DAXX expression, in some tumors, tend to have a
worse prognosis.8
In addition to this, numerous studies have shown that
DAXX mutations are present in various types of tumors, such
as oral cancers, pancreatic neuroendocrine tumors, urothelial
carcinomas, prostate cancers, glioblastomas, ovarian cancers,
and so on.9–14 While per contra to previously suggested, other
studies have shown that loss of DAXX (nuclear) correlates with
worse clinical behaviors.9–14 Furthermore, given the important
regulatory role of DAXX in apoptosis, multiple preliminary
studies have shown promising therapeutic value in DAXXtargeted cancer treatment (in vivo studies).15,16
Despite this, there have been no studies examining the role
of DAXX in endometrial carcinomas.
In view of these considerations, the aim of this study was to
examine the subcellular localization of DAXX in tissue samples
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Table 1. DAXX staining across the various types of endometrial carcinomas. (UEC/DDEC, clear cell, serous and endometrioid).
Tumor type (N = 65)

Percentage of lesional cells with DAXX nuclear positivity
0%–50%

50%–75%

>75%

UEC/DDEC (n = 13)

0

2

11 (on UC component)

Clear cell carcinoma (n = 14)

5

4

5

Serous carcinoma (n = 8)

2

0

6

 FIGO G1 (n = 12)

10

1

1

 FIGO G2 (n = 12)

11

1

0

 FIGO G3 (n = 6)

0

3

3

Secretory endometrium (n = 5)

3

2

0

Proliferative endometrium (n = 8)

2

0

6

Endometrioid type carcinoma (n = 30)

Benign endometrium (n = 13)

Abbreviations: DAXX, death domain-associated protein 6; FIGO, The International Federation of Gynecology and Obstetrics; UEC/DDEC, undifferentiated/dedifferentiated
type; G1, grade 1; G2, grade 2; G3, grade 3.

from various histotypes of endometrial carcinomas. This was
performed to provide some novel insights into (1) whether loss
of DAXX is present in uterine carcinomas and (2) whether
DAXX expression is the same across all the uterine carcinoma
subtypes.

Materials and Methods
Case selection and classification
A total of 65 uterine carcinomas were identified in our institutional pathology database from 2010 to 2017. A subset of 30
endometrioid type (12 FIGO [The International Federation
of Gynecology and Obstetrics] grade 1, 12 FIGO grade 2, and
6 FIGO grade 3), 8 serous type, 14 clear cell type (CCC), and
13 undifferentiated/dedifferentiated type (UEC/DDEC)
were reviewed independently by 2 senior gynecological
pathologists to confirm the diagnosis and to identify the best
tumor-containing slide. Another random selection of 13
benign endometrium biopsies were also included in the study
for comparison. The endometrium specimens included 5 cases
of secretory endometrium and 8 cases of proliferative endometrium. Patient ages at resection ranged from 39 years to
90 years old, with all specimens being hysterectomies. The tissues were prepared in paraffin-embedded blocks for pathological diagnosis.

Immunohistochemical analysis
Immunohistochemical stains for DAXX (Anti-DAXX [Sigma
Life Science; HPA008736, 1:100]) were assessed on tissue sections. The staining protocol and controls are submitted in
Supplemental material.

Loss of DAXX expression was semi-quantified as <50%
nuclear labeling within the tumor cells, 50% to 75% (dominant
pattern) and more than 75% (significant pattern). Tumors with
absent DAXX expression were required to have positive internal controls (normal endothelial, stromal, or inflammatory
cells) before being considered negative. All the staining was
performed at the Immunopathology Laboratory of Long
Island Jewish Medical Center (Northwell Health System, New
Hyde Park, NY).

Statistics

Statistical analysis was performed using the 2-tailed Fisher
exact test and Student t tests (vassarstats.net) depending on the
type of variables being analyzed. This work was approved by
the Institutional Review Board of Northwell Health Systems.

Results

DAXX staining was performed on a total of 65 cases: a subset
of 30 endometrioid type (12 grade 1, 12 grade 2, and 6 grade 3),
8 serous type, 14 clear cell type, and 13 UEC/DDEC together
with an additional 13 benign endometrium (5 secretory phase
and 8 proliferative phase) for comparison (Table 1). The mean
ages for endometrial carcinoma patients were 63.4 ± 13.4
(range = 55-90) years, while the ages for benign endometrium
were 45.2 ± 2.5 (range = 39-48) years (P < .05).
All of the cases showed both nuclear and cytoplasmic staining. The percentage of nuclear staining was quantified in each
case. A variable spectrum of nuclear DAXX expression was
identified among different tumor histotypes (Figure 1).
Among the endometrial carcinoma cases, 2/65 (3.1%) were
FIGO stage IV, 8/65 (12.3%) were FIGO stage III, 11/65

Jin et al

3

Figure 1. Immunostaining patterns of DAXX in different histotypes of endometrial cancers: (A) Serous type with low power at 4× and (inlet, 40×), (B)
clear cell type with low power at 10× (inlet, 40×), (C) FIGO 3 endometroid type with low power at 4× (inlet 40×), and (D) low-grade endometroid type with
low power at 4×and (inlet, 40×). At high power (40×), high-grade endometrial carcinomas (A, B, C) all show strongly retained nuclear staining of DAXX in
tumor cells while low-grade endometrial carcinomas (D) mainly show loss of nuclear DAXX in tumor cells.
Abbreviation: DAXX, death domain-associated protein 6; FIGO, The International Federation of Gynecology and Obstetrics.

Table 2. Comparison of immunostaining pattern of DAXX across endometrial carcinomas (low and high grade) with benign endometrium (secretory
and proliferative).
Group

High-grade
endometrial
carcinomas (n = 41)

DAXX nuclear > 50%

34

DAXX nuclear < 50%

7

P (compared with high grade)
P (compared with low grade)

Low-grade
endometrial
carcinomas (n = 24)

Secretory
endometrium
(n = 5)

Proliferative
endometrium
(n = 8)

3

2

6

21

3

2

<.001

.06

.63

.19

.0021

<.001

Abbreviation: DAXX, death domain-associated protein 6.
Two-tailed Fisher exact test was used to compare between each group. P < .05 is considered statistically significant.

(16.9%) were FIGO stage II, and 44/65 (67.7%) were FIGO
stage I. When using the cut-off value of 50%, the dominant
(50%-75%) and significant pattern (>75%) nuclear DAXX
expression were observed in 9/14 (64.3%) CCC, 6/8 (75%)
serous carcinoma, and 6/6 (100%) FIGO grade 3 endometrioid carcinoma. In contrast, only 2/12 (16.7%) FIGO grade 1
and 1/12 (8.3%) FIGO grade 2 endometrioid carcinomas
showed a (dominant or significant) nuclear staining pattern.
Nuclear DAXX expression was found to be significantly
higher in high-grade endometrial carcinomas (34/41) than in
low-grade endometrial carcinomas (3/24) (82.9% vs 12.5%,
P < .0001) (Table 2).

Especially, in the 11 DDEC cases, all the differentiated
components (low grade) showed less DAXX staining (nuclear)
retention compared with the undifferentiated components,
where DAXX was mainly retained (Figure 2).
The normal endometrium interestingly showed different
staining patterns (between secretory and proliferative types)
(Figure 3). By using the cut-off of 50%, the proliferative endometrium had 6/8 (75%) cases show a dominant nuclear staining pattern; this was higher when compared with secretory
endometrium (2/5, 40%). Ultimately, there was no statistically
significant difference between the groups (P = .29). However,
when a cut-off of 75% was used, significant nuclear DAXX
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Figure 2. Dedifferentiated endometrial carcinoma at low power (4×) (A) showing 2 different histological patterns including undifferentiated component at
the lower left and differentiated component at the lower right; at high power (40×) (B) showing the undifferentiated component predominantly with nuclear
staining while the differentiated component (C) with loss of nuclear staining.

Figure 3. Immunostaining patterns of DAXX in normal endometrium: (A) Secretory endometrium with low power at 4× (inlet, 40×) and (B) proliferative
endometrium with low power at 10× (inlet, 40×). The secretory endometrium (A) at high power shows loss of DAXX nuclear staining, while in contrast the
proliferative endometrium (B) at high power shows retained nuclear DAXX staining.
Abbreviation: DAXX, death domain-associated protein-6.

staining was more frequently seen in proliferative endometrium when compared with secretory endometrium (P = .021).
The secretory endometrium tended to have lower nuclear

DAXX than in high-grade cancers (P = .06), although there
was no difference between high-grade cancers and proliferative
endometrium (P = .63). In contrast, proliferative endometrium
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showed higher nuclear DAXX than low-grade carcinoma
groups (P = .0021), although there was no difference between
low-grade carcinoma groups and secretory endometrium
(P = .19). The results are summarized in Table 2.

Discussion

In our current study, DAXX analysis yielded variable patterns
among the different endometrial histotypes. High-grade endometrial carcinomas tended to have higher percentage of nuclear
staining (in tumor cells) than low-grade types. The normal
endometrium also presented with different staining patterns,
with more nuclear staining being seen in proliferative endometrium than secretory endometrium. Although expression of
DAXX has been studied in a variety of tumors, no such studies
have been performed in endometrial carcinomas.
DAXX was originally identified as pro-apoptotic factor,4
with its role in apoptosis being controversial and possibly
related to its subcellular localization.5 It has long been known
that protein and its subcellular localization can be closely
related to tumor progression.5 For example, S100A4 is a prognostic variable in breast cancer, which varies depending on its
subcellular localization.17–19 Similarly and as previously mentioned, while in neurons, the function of DAXX varies also
according to its localization: when DAXX is located in the
nucleus, it is anti-apoptotic, whereas when it is localized in the
cytoplasm, it is pro-apoptotic.7 In addition, recent findings in
gastric cancers showed that an increased DAXX (nuclear/cytoplasmic ratio) was significantly higher in cancer tissues than in
adjacent normal tissues.20 The possible anti-apoptotic role of
DAXX is also implied in our observational study, which suggests that nuclear DAXX is higher in normal proliferative
endometrium (possibly being anti-apoptotic) than in secretory
endometrium (possibly being pro-apoptotic), while nuclear
DAXX expression also showed higher expression in high-grade
endometrial carcinomas than in low-grade carcinomas (using 2
different cut-off points). More convincingly, in dedifferentiated cases, almost all the tumors cells retained nuclear staining,
while the adjacent differentiated components showed less
nuclear staining.
Worth mentioning is that the nuclear expression of DAXX
was not significantly different when comparing high-grade
endometrial carcinomas and proliferative endometrium. This
finding is not surprising as endometrial carcinomas are usually
seen in the background of proliferative endometrium.1
However, ultimately, in the progression to high-grade endometrial carcinomas, other proteins are also necessary (in addition
to DAXX).
Interestingly, most of the low-grade endometrial carcinomas showed much less nuclear DAXX expression. Recently,
with the advent toward molecular classification of endometrial
carcinomas, genomic information has been gradually integrated into traditional histological classification systems.2 It
has been shown that endometrioid type carcinomas actually
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represent a heterogeneous group of carcinomas with different
molecular signatures, such as copy-number low variant, POLE
(DNA Polymerase Epsilon, Catalytic Subunit) gene hotspot
mutated, and MSI-H (microsatellite instability-high), while
the high-grade endometrial carcinomas tend to be high copynumber variant.2,3 Therefore, low nuclear DAXX expression, in
either low- or high-grade groups, may follow a different
molecular pathway than those of high nuclear DAXX
expression.
Whether loss of nuclear staining is due to DAXX mutations
or protein relocation currently remains unknown. Studies have
shown that loss of nuclear DAXX on IHC may be a surrogate
marker for the presence of DAXX mutations,5 which may
partly explain its pathogenesis in low-grade endometrial carcinomas. Conversely, in high-grade endometrial carcinomas,
retained nuclear DAXX may stem from reduced nuclear-tocytoplasm protein relocation, which establishes one of the crucial hallmarks of carcinogenesis (self-initiated continuous
tumor proliferation). We did not perform molecular analysis,
which is a limitation in our current study. Therefore, whether
loss of nuclear staining is due to DAXX mutations, protein
relocation, or something else remains to be further elucidated.
Finally, regarding the DAXX staining pattern of the uninvolved
biopsy-retrieved endometrium, in our study, strong nuclear
staining was seen in the proliferative but not in secretory endometrium. This is possibly due to the anti-apoptotic/proliferative role of DAXX.21 Ultimately, however, only further research
will allow us to fully understand its complete role.
Another newly established function of DAXX is its regulation of telomeres.5 Telomere elongation and maintenance is
likely partially responsible for cancer progression.5,22 There are
2 main telomere maintenance mechanisms that have been
described: telomerase dependent and telomerase independent
(such as alternative lengthening of telomeres [ALT]).22 A
common mechanism of carcinogenesis in telomerase-dependent pathway is mutations in the promoter of the telomerase
reverse transcriptase (TERT) gene. Whereas in the telomerase
independent pathway, an ALT (alternative lengthening of telomeres) phenotype, which uses homologous recombination for
telomere length maintenance (instead of activation of the telomerase enzyme), is ultimately implicated in the progression of
multiple cancer types (especially in brain tumors and
sarcomas).23,24
DAXX also interacts with ATRX (alpha-thalassemia/mental retardation syndrome X-linked) to form a protein complex,
which can function as an H3.3-specific histone chaperone,
while incorporating H3.3 into telomeres, thus contributing to
the regulation of ALT.5,25 It has been reported that 80% of
tumors with an ALT phenotype have mutations in either
ATRX or DAXX.5 Loss of ATRX and/or DAXX has been
associated with an ALT phenotype in multiple tumor types,
such as sarcomas, pancreatic neuroendocrine tumors, gliomas,
and uterine leiomyosarcomas.14,26–29 However, only up to 3% of
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endometrial carcinomas harbor an ALT phenotype.24
Therefore, the common loss of DAXX in low-grade endometrial carcinomas might not explain its role in contributing to
the regulation of ALT.
Finally, endometrial carcinoma represents a heterogeneity of
different histotypes. Each type may carry different histopathological features and genetic signatures.2,3 In our study, the heterogeneous DAXX expression pattern found in its different
histotypes may suggest a potential role for target therapy. In
vitro studies have already established its therapeutic value, as
inhibiting DAXX was found to arrest the growth of glioblastoma in mice models.29 In the therapeutic context, several
approaches to target DAXX have been investigated, including
using peptides or small molecules to disrupt DAXX interaction
with chromatin-associated proteins.30
Our study is not without limitations. The major concern is
that we were not able to validate the specificity of the antibody by Western blot. Although we had positive and negative
controls (IHC) for DAXX, ideally, a reaction with DAXXrich and DAXX-deficient tissue on blots can give more convincing results. Second, we did not have precursor lesions in
our study, including atypical endometrial hyperplasia with
atypia. Including such cases would give us a clearer spectrum
of DAXX expression in the pathogenesis of endometrial
carcinomas.
In summary, we conclude that loss of DAXX protein expression is associated with low-grade endometrial carcinomas.
With DAXX expression being found to be significantly higher
in high-grade endometrial carcinomas, it is possible that future
cancer therapies could target this pathway, which may have significant implications for treating patients with endometrial
carcinomas.
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